Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC).
Marlo A. Blazer
No relevant relationships to disclose
Christina Sing-Ying Wu
No relevant relationships to disclose
Richard M. Goldberg
Consultant or Advisory Role - Bayer (U); Jennerex Biotherapeutics (U); Lilly; Pfizer; Sanofi (U)
Honoraria - Sanofi
Research Funding - Bayer; Sanofi
Gary S. Phillips
No relevant relationships to disclose
Carl Richard Schmidt
No relevant relationships to disclose
Peter Muscarella
No relevant relationships to disclose
Samer S El-Dika
No relevant relationships to disclose
Jon P Walker
No relevant relationships to disclose
Somashekar Gopala Krishna
No relevant relationships to disclose
J. Royce Groce
No relevant relationships to disclose
Evan John Wuthrick
No relevant relationships to disclose
Terence M Williams
No relevant relationships to disclose
David Efries
No relevant relationships to disclose
Yahna T. Smith
No relevant relationships to disclose
Kris Mathey
No relevant relationships to disclose
Mandy Wagner
No relevant relationships to disclose
Josh Reardon
No relevant relationships to disclose
Edwin Christopher Ellison
No relevant relationships to disclose
Mark Bloomston
No relevant relationships to disclose
Tanios S. Bekaii-Saab
No relevant relationships to disclose